Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro-Reference-Cited by-同舟云学术

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro

Published:2020-10-09 Issue: Volume:8 Page:
ISSN:2296-634X
Container-title:Frontiers in Cell and Developmental Biology
language:
Short-container-title:Front. Cell Dev. Biol.

Author:

Peters Godefridus J.,van Gemert Frank P. A.,Kathmann Ietje,Reddy Guru,Cillessen Saskia A. G. M.,Jansen Gerrit

Publisher

Frontiers Media SA

Subject

Cell Biology,Developmental Biology

Reference54 articles.

1. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.;Azzoli;Clin. Cancer Res.,2007

2. Analysis of drug interactions.;Bijnsdorp;Methods Mol. Biol.,2011

3. Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells.;Bijnsdorp;Biochem. Pharmacol.,2010

4. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.;Buckley;J. Transl. Med.,2007

5. Antitumor activity of ZD1694 (Tomudex) against human head and neck cancer in nude mouse models: role of dosing and schedule and plasma thymidine.;Cao;Clin. Cancer Res.,1999

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of l-leucovorin uptake and metabolism in the modulation of 5-fluorouracil efficacy and antifolate toxicity;Frontiers in Pharmacology;2024-08-21

2. Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism;Molecular Cancer Therapeutics;2024-03-25

3. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL);Clinical Epigenetics;2023-08-02

4. The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs: Exploring Potential Mechanisms of Resistance;Current Medicinal Chemistry;2023-04

5. Ultrasensitive response explains the benefit of combination chemotherapy despite drug antagonism;2023-02-27